Safety and pharmacodynamics of intranasal <scp>GSK</scp>2245035, a <scp>TLR</scp>7 agonist for allergic rhinitis: A randomized trial
Anne K. Ellis(Queen's University), L. A. Lee(GlaxoSmithKline (United Kingdom)), Wendy Powley(GlaxoSmithKline (United Kingdom)), Daphne Tsitoura, Diana Quint(GlaxoSmithKline (United Kingdom))
Cited by 32
Related Papers
Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis
|Journal of Allergy and Clinical Immunology|2020|690
Drug allergy: A 2022 practice parameter update
|Journal of Allergy and Clinical Immunology|2022|533
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
|International Forum of Allergy & Rhinology|2023|475
Anaphylaxis—a practice parameter update 2015
|Annals of Allergy Asthma & Immunology|2015|473
Rhinitis 2020: A practice parameter update
|Journal of Allergy and Clinical Immunology|2020|420